Taking a patient-centered approach, Indivior is developing innovative treatments for addiction to opioids, alcohol, and stimulants, as well as accompanying illnesses such as schizophrenia.
...selective blockade of the OX1 receptor decreases drug seeking and prevents relapse or reinstatement of drug-seeking behavior during abstinence in animal models of addiction. Indivior has entered into a partnership with C4X Discovery to develop their lead molecule, C4X3256, a selective OX1 receptor antagonist.
Drug development company C4X Discovery is using the same technology used to build the incredibly popular Fortnite video game to develop medicines in the digital world that it hopes can make an impact in the real world.
‘Pop into the labs of Manchester biotech C4X Discovery and you could be in for a surprise. Instead of scientists perched at their work stations peering down microscopes or poring over data, you might find them walking around, arms outstretched, holding what would appear to be imaginary objects.
These scientists haven’t gone mad. They’re pioneers of a new field in drug discovery that combines science with the sort of virtual reality technology typically associated with gaming. Using a headset and hand controls they’re transported into 3D chambers where they can access a database of virtual molecules to pull and twist to see how they fit together.’
5 October 18 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that at the General Meeting held earlier today in connection with the Company’s Placing and Open Offer at a price of 90 pence per new Ordinary Share, details of which were announced on 18 September 2018, all resolutions put to shareholders were duly passed.
Proceeds of fundraise will support the Company’s strategy of becoming the world’s most productive, self-sustaining drug discovery engine
18 September 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces a proposed conditional Placing of Placing Shares with existing and new institutional investors to raise up to approximately £10.0 million before expenses at the Issue Price of 90 pence per new Ordinary Share.